A study on page 239 shows that death-inducing T cells kill smooth muscle cells in atherosclerotic plaques. Sato et al. show that this lethal T cell activity is heightened in patients with heart disease, which could destabilize the plaques in these patients and make them more prone to rupture.

Figure 1TRAIL-expressing CD4^+^ T cells trigger apoptosis of vascular smooth muscle cells (red) in atherosclerotic plaques

The narrowing of arteries is a natural process caused by the gradual deposition of fat and cholesterol into artery walls. The buildup of arterial plaques (atherosclerosis) is a long-term process that, for some, culminates in acute coronary syndromes (ACSs) such as heart attack and cardiac arrest. These acute attacks are caused by the sudden rupture of atherosclerotic plaques---an event that may happen more readily in some individuals than in others.

Plaques that contain immune cells such as macrophages and T cells are the most vulnerable to rupture, although the mechanism behind this observation is not well understood. Now, Sato and colleagues show that CD4^+^ T cells that infiltrate atherosclerotic plaques trigger the death of vascular smooth muscle cells (VSMCs), a process proposed to destabilize the plaques.

The plaque-infiltrating T cells expressed high levels of TRAIL, a death receptor normally used by T cells and NK cells to destroy cancerous cells. The expression of this receptor was required for T cells to induce apoptosis in VSMCs (which expressed the TRAIL receptor DR5) both in vitro and in vivo. CD4^+^ T cells from patients with ACS expressed higher levels of TRAIL when activated and were more adept at triggering VSMC apoptosis in vitro compared with T cells from healthy individuals, possibly explaining why these individuals developed acute disease while others were spared. What causes plaque-residing VSMCs to express DR5 and why T cells infiltrate the plaques in some individuals is not yet known.

These results demonstrate that the TRAIL pathway---previously thought to induce death only in cancer cells---can also trigger apoptosis in nontransformed cells. A recombinant form of TRAIL is currently in clinical trials for the treatment of certain cancers, a therapeutic approach that might need reevaluation in light of its potential negative effects on patients with atherosclerosis.![](iti_end.jpg)

[^1]: <hvanepps@rockefeller.edu>
